CollinsFS. Lessons learned from leading NIH. Science. 2022; 375:123–123. DOI: 10.1126/science.abn7743.
2.
NurkS, KorenS, RhieA, et al.The complete sequence of a human genome. Science. 2022; 376:44–53. DOI: 10.1126/science.abj6987.
3.
ErikssonM, BrownWT, GordonLB, et al.Recurrent de novo point mutations in Lamin A Cause Hutchinson–Gilford Progeria Syndrome. Nature. 2003; 423:293–298. DOI: 10.1038/nature01629.
4.
KoblanLW, ErdosMR, WilsonC, et al.In vivo base editing rescues Hutchinson–Gilford Progeria Syndrome in mice. Nature. 2021; 589:608–614. DOI: 10.1038/s41586-020-03086-7.
5.
KanterJ, WaltersMC, KrishnamurtiL, et al.Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022; 386:617–628. DOI: 10.1056/NEJMoa2117175.
6.
EsrickEB, LehmannLE, BiffiA, et al.Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. N Engl J Med. 2021; 384:205–215. DOI: 10.1056/NEJMoa2029392.
7.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021; 384:252–260. DOI: 10.1056/NEJMoa2031054.
8.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021; 385:493–502. DOI: 10.1056/NEJMoa2107454.
9.
LiC, WangH, GeorgakopoulouA, et al.In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a Mouse Model. Mol Ther. 2021; 29:822–837. DOI: 10.1016/j.ymthe.2020.09.001.
10.
CollinsFS, MetherallJE, YamakawaM, et al.A point mutation in the Aγ-globin gene promoter in greek hereditary persistence of fetal haemoglobin. Nature. 1985; 313:325–326. DOI: 10.1038/313325a0.
